Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.

[1]  M. Elisaf,et al.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. , 2005, Clinical chemistry.

[2]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[3]  Yasuo Ikeda,et al.  Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. , 1999, Biochemical and biophysical research communications.

[4]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[5]  Joseph S Alpert,et al.  [Universal definition of the myocardial infarction]. , 2008, Kardiologia polska.

[6]  M. Elisaf,et al.  Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia , 1997, European journal of clinical investigation.

[7]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[8]  R. Wilensky,et al.  Lipoprotein-associated phospholipase A2 and atherosclerosis , 2009, Current opinion in lipidology.

[9]  L. Cardon,et al.  Carriage of the V279F Null Allele within the Gene Encoding Lp-PLA2 Is Protective from Coronary Artery Disease in South Korean Males , 2011, PloS one.

[10]  M. Yen,et al.  Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. , 2000, Atherosclerosis.

[11]  Медицина.  Auckland City Hospital , 2011 .

[12]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[13]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[15]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  H. Krumholz.  Lipoprotein-Associated Phospholipase A , 2001 .

[17]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[18]  C. Held,et al.  Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. , 2010, American heart journal.

[19]  M. Hanefeld,et al.  The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.

[20]  U. Ikeda,et al.  Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. , 2002, Atherosclerosis.

[21]  G. Zimmerman,et al.  Human macrophages secret platelet-activating factor acetylhydrolase. , 1990, The Journal of biological chemistry.

[22]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.